Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

28.76USD
4:02pm EDT
Change (% chg)

$-0.68 (-2.31%)
Prev Close
$29.44
Open
$29.26
Day's High
$29.29
Day's Low
$28.47
Volume
3,343,632
Avg. Vol
1,984,483
52-wk High
$56.44
52-wk Low
$28.47

Latest Key Developments (Source: Significant Developments)

Sosei Group unit Heptares to receive $5 million milestone
Thursday, 18 May 2017 03:49am EDT 

May 18(Reuters) - Sosei Group Corp <4565.T>:Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist, discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd <<>> has triggered a $5 million payment from Teva to Heptares under the terms of their licensing and drug-discovery agreement signed in 2015.  Full Article

Teva announces FDA approval of AUSTEDO tablets for treatment of chorea associated with huntington’s disease
Monday, 3 Apr 2017 05:04pm EDT 

Teva Pharmaceutical Industries Ltd - : Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with huntington’s disease .AUSTEDO is expected to be available in U.S. within next 3 weeks..  Full Article

Appaloosa LP dissolves share stake in Citigroup, Bank of America - SEC Filing
Tuesday, 14 Feb 2017 04:47pm EST 

Appaloosa LP : Appaloosa lp dissolves share stake in citigroup inc . Appaloosa lp dissolves share stake in bank of america corp . Appaloosa lp dissolves share stake in general motors co . Appaloosa lp takes share stake of 4.8 million shares in pfizer inc . Appaloosa lp takes share stake of 3.3 million shares in mylan n v . Appaloosa lp takes share stake of 5.1 million adrs in teva pharmaceutical . Appaloosa lp ups share stake in facebook inc by 47.0 percent to 2.2 million class a shares . Appaloosa lp ups share stake in qualcomm inc by 55.6 percent to 1.4 million shares . Appaloosa lp ups share stake in southwest airlines co by 106.4 percent to 1.2 million shares . Appaloosa lp dissolves share stake in synchrony financial .Appaloosa lp - change in holdings are as of dec 31, 2016 and compared with the previous quarter ended as of sept 30, 2016.  Full Article

Teva said to weigh options for branded generics to reduce debt- Bloomberg, citing sources
Monday, 13 Feb 2017 10:30am EST 

: Teva said to weigh options for branded generics to reduce debt - Bloomberg, citing sources . Business could be valued at several billion dollars, and Teva may also consider spinning off the unit - Bloomberg, citing sources . Teva's primary focus is finding a new chief executive officer after Erez Vigodman stepped down suddenly earlier this month - Bloomberg,citing source . Teva may also opt to sell other non-core assets, such as its active pharmaceutical ingredients business - Bloomberg citing sources Source : http://bloom.bg/2lHiR1Z ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Teva board seeks new CEO with extensive pharma experience
Monday, 13 Feb 2017 08:00am EST 

Teva Pharmaceutical Industries Ltd : Teva chairman: board has begun search for new CEO with extensive pharmaceutical experience . Teva interim CEO says "committed" to 2017 EPS target range, will cut costs if needed to achieve it . Teva interim CEO: Copaxone 40 mg competition in February would cut 2017 revenue by $1-$1.3 billion, EPS by $0.75-$0.95 . Teva says majority of U.S. generic launches expected only in second half of 2017 Further company coverage: [TEVA.TA] (Reporting by Tova Cohen) ((tova.cohen@thomsonreuters.com;)).  Full Article

Teva and Celltrion report exclusive biosimilar commercial partnership
Thursday, 6 Oct 2016 08:00am EDT 

Teva Pharmaceutical Industries Ltd : Teva will pay Celltrion healthcare $160 million upfront . Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars . Exclusive partnership to commercialize two of Celltrion's MAB biosimilar candidates in U.S. and canada . Celltrion has responsibility for completing all clinical development and regulatory activities .Of $160 million upfront payment, up to $60 million is refundable or creditable under certain circumstances.  Full Article

Teva announces sale of UK and Ireland actavis assets and operations
Wednesday, 5 Oct 2016 11:00am EDT 

Teva Pharmaceutical Industries Ltd : Teva announces sale of UK and Ireland actavis assets and operations . Deal for GBP 603 million . Sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England . Teva retains a number of actavis non-overlapping generic products plus certain specialty medicines and otc products . Greenhill & Co. are serving as financial advisors to Teva, and Pinsent Masons are serving as legal counsel to Teva in respect of this transaction .Divestment of certain specified actavis generics assets and operations in UK and Ireland was part of an undertaking that Teva made to European commission.  Full Article

U.S. court rules in favor of Depomed in its patent litigation for NUCYNTA
Friday, 30 Sep 2016 03:55pm EDT 

Depomed Inc : Depomed prevails in Nucynta franchise ANDA litigation providing market exclusivity until December 2025 . Company intends to appeal court's finding as it relates to infringement of '130 patent . Depomed inc says '130 patent covers Nucynta ER until March 2029 . Court found U.S. patent nos. 7,994,364 and RE39,593 to be valid and infringed by defendants . With court's ruling, Depomed expects market exclusivity until december 2025 for Nucynta ER, Nucynta and Nucynta oral solution .Judge ruled in favor of depomed in company's patent litigation against all three filers of abbreviated new drug applications for Nucynta.  Full Article

Regeneron, Teva collaborate to develop, commercialize Fasinumab
Tuesday, 20 Sep 2016 07:00am EDT 

Regeneron Pharmaceuticals Inc : Regeneron and Teva announce global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain . Teva to pay co $250 million upfront and share equally in global commercial value, and ongoing research and development costs of about $1 billion .Regeneron is eligible to receive development and regulatory milestone payments and additional payments based on net sales.  Full Article

MDxHealth and Teva Pharmaceuticals sign distribution deal
Wednesday, 31 Aug 2016 01:06am EDT 

Mdxhealth SA : MDxHealth and Teva Pharmaceuticals sign distribution agreement for SelectMDx in Israel .Teva Pharmaceuticals will be exclusive distributor of selectMDx for prostate cancer test in Israel.  Full Article

More From Around the Web

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.